CyberKnife Therapy Prevents Prostate Cancer in Men at Low to Intermediate Risk, Study Says

CyberKnife Therapy Prevents Prostate Cancer in Men at Low to Intermediate Risk, Study Says
Men at low risk of prostate cancer who got radiation therapy with Accuray's CyberKnife System were still disease-free after seven years, as were 88.5 percent of men at intermediate risk, concluded a clinical trial by the medical device manufacturer. At seven years after treatment, disease-free survival rates were 100 percent for patients with low-risk of prostate cancer and 88.5 percent for intermediate-risk patients. The study, “Five-Year Outcomes From a Prospective Multi-Institutional Trial of Heterogeneous Dosing Stereotactic Body Radiotherapy (SBRT) for Low- and Intermediate-Risk Prostate Cancer,” was presented at the Feb. 16-18 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), held Feb. 16-18 in Orlando, Florida. The CyberKnife is a non-invasive, frameless radiosurgical device that delivers stereotactic body radiation therapy (SBRT) throughout the body with very high precision. It also helps doctors track and correct, in real-time, delivery of radiation to the prostate. The Phase 2 study (NCT02225262) enrolled 259 prostate cancer patients, 112 of whom were low risk 147 intermediate risk. Doctors, using CyberKnife, treated the men over four days with 38 Gy radiation fractions. The study aimed to assess disease-free survival and measure the incidence of acute and late genitourinary and gastrointestinal side effects after the treatmen
Subscribe or to access all post and page content.

One comment

  1. Chris O'Neill says:

    “disease-free after seven years”

    This study shows nothing about the end-point that men care about, overall survival, which is always unaffected by low, intermediate or even high risk prostate cancer detected after seven years of PSA screening anyway. The same applies to prostate cancer-specific survival so this study is only of academic interest.

Leave a Comment

Your email address will not be published. Required fields are marked *